Most participants had diabetes (SGLT2 inhibitors + DT group: n = 102, 41.13%; DT group: n = 88, 35.48%; p = .0506), and most did not suffer from Chronic Kidney Disease (SGLT2 inhibitors + DT group: n = 99, 39.92%; DT group: n = 92, 37.10%; p = .3653). This evidence concerns the gene SLC5A2 and chronic kidney disease.